Objective: To evaluate the therapeutic effect of modified FLAG regimen in the management of refractory acute myeloid leukemia (AML).
Methods: Sixteen patients with refractory AML were divided into two groups. In modified FLAG regimen group (n=10), the patients received fludarabine (Flu, 50 mg/d, VDx5 d) and Ara-c (200 mg/d, VDx5 or 7 d). The regimen for classic FLAG group (n=6) consisted of Flu (50 mg/d, VDx5d), Ara-C (500 or 1,000 mg/d, VDx5d) and G-CSF (300 microg/d, x5 d, subcutaneously injected 4-6 hours before chemotherapy). Each patient received subcutaneous G-CSF (300 microg/d) when the white blood cell count was lower than 1.0x10(9)/L till the condition was corrected.
Results: The total complete remission(CR) rate of the 16 patients was 50% (8/16). Seven patients in modified group achieved CR (70%) and only one of the classic group did (17%, P<0.05). Episodes of infections were lower in modified group than in the classic group (50% vs 83%).
Conclusion: Modified FLAG regimen is more likely than classic FLAG regimen to achieve CR and reduce infections in patients with refractory AML.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease.
Hematol Oncol
January 2025
Department of Internal Medicine (DiMI), Clinic of Hematology, University of Genoa, Genoa, Italy.
Secondary acute myeloid leukemia (s-AML) is associated with inferior outcomes with conventional chemotherapy, and fludarabine combinations (FLAG-Ida) have been tested to improve results. More recently, CPX-351 resulted superior to conventional 3 + 7 in s-AML patients. In the UK NCRI AML19 trial, AML patients were randomized to receive either FLAG-Ida or CPX-351.
View Article and Find Full Text PDFEndoscopic Significance of Incidental Upper Gastrointestinal Wall Thickness Detected on Computed Tomography Scans.
Cureus
November 2024
Internal Medicine, Royal Preston Hospital, Preston, GBR.
Background Incidental upper gastrointestinal wall thickness (GIWT) is a nonspecific finding often observed on computed tomography (CT) scans performed to investigate patients admitted with various symptoms both gastrointestinal (GI) and non-GI. Its clinical significance is uncertain, and patients often undergo endoscopic evaluation under an urgent cancer pathway to exclude malignancy. We aimed to conduct this study to determine how well the CT findings correlated endoscopically.
View Article and Find Full Text PDFDose-Reduced FLA-IDA in Combination with Venetoclax Is an Effective and Safe Salvage Therapy in Relapsed and Refractory Acute Myeloid Leukemia (R/R AML).
Cancers (Basel)
November 2024
Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Despite the development of targeted therapies in first-line AML, complete remissions (CR) cannot be achieved in 30-40%, and relapse rates remain high. In R/R AML the intensive treatment regimen of fludarabine, cytarabine, idarubicin combined with venetoclax (FLA-VIDA) showed improved remission rates compared to FLA-IDA. In this retrospective single-center analysis, we investigated the efficacy and safety of dose-reduced FLA-IDA with and without venetoclax to minimize the risk of infectious complications and excessive myelosuppression; Methods: Between 2011 and 2023, 89 R/R AML patients were treated with dose-reduced FLA-IDA (fludarabine 30 mg/m day 1-4, cytarabine 2000 mg/m day 1-4, idarubicin 10 mg/m day 1 + 4).
View Article and Find Full Text PDFLipemia retinalis following FLAG-Ida protocol in an 11-year-old patient with acute myeloid leukemia.
Eur J Ophthalmol
January 2025
Department of Pediatric Hematology and Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Introduction: We report a case of early-onset lipemia retinalis secondary to the FLAG-Ida protocol in the treatment of acute myeloid leukemia (AML) in an 11-year-old girl.
Case Report: An 11-year-old patient, diagnosed with AML at four months old, experienced a relapse and was treated with the FLAG-Ida protocol (fludarabine, idarubicin, granulocyte-colony stimulating factor, and high-dose cytarabine). Prior to allogeneic stem cell transplantation, she underwent a pre-transplantation eye examination.
Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study.
Front Immunol
September 2024
Nanfang-Chunfu Children's Institute of Hematology & Oncology, TaiXin Hospital, Dongguan, China.
Introduction: Pre-HSCT disease control, suboptimal long-term prognosis, and a high recurrence incidence (RI) continue to pose significant challenges for hematopoietic stem cell transplantation (HSCT) in juvenile myelomonocytic leukemia (JMML) patients.
Methods: This retrospective cohort study assessed the effectiveness of a decitabine (DAC)-based protocol in JMML patients undergoing HSCT. The pre-HSCT treatment includes initial and bridging treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!